

2017 Outcomes to 2018 Universal Rx Prime Drug Formulary Changes

The 2018 Universal Rx Prime Drug Formulary, coupled with effective plan design, will continue to assist sponsors working to reach the best balance between drug appropriateness and cost objectives. I have summarized in this memorandum notable changes in the 2018 Universal Rx Prime Drug Formulary.

1. The following BRAND products will move from Non-Formulary to Preferred BRAND designation. In many cases the Copay Tier will decrease from Tier 3 to Tier 2:

Advate	Ibrance	Revlimid
Albenza	Ilaris	Reyataz
Alinia	Imbruvica	Rozerem
Androderm	Isentress	Sabril
Atripla	Jakafi	Serostim
Atrovent HFA	Lo Loestrin	Simponi
Banzel	Menopur	Skyla
Betaseron	Natacyn	Sporanox sol
Biltricide	Neulasta	Stivarga
Brisdelle	Nexium Packets	Stribild
Celontin	Ninlaro	Sustiva
Cerdelga	Norvir	Sutent
Chantix	Novotwist needles	Synagis
Complera	Noxafil	Tagrisso
Cortifoam	Odefsey	Tasigna
Descovy	Ofev	Tivicay
Dilantin	Onfi	Triumeq
Edarbi	Oracea	Truvada
Edarbyclor	Orkambi	Tykerb
Eligard	Performist	Viread
Elmiron	Picato	Votrient
Emverm	Pomalyst	Xalkori
Entyvio	Prezista	Xifaxan 200mg
Esbriet	Pulmozyme	Xyrem
Fareston	Purixan	Zelboraf
Flector	Rasuvo/Otrexup	Zortress
Genvoya	Regranex Gel	Zovirax
Hizentra	Relenza	

2. Drugs No Longer on the Market

FORADIL

INCIVEK

OPANA ER

3. The following BRAND products will move to Non-Formulary designation due to new generic alternatives released in 2017.

ANDROGEL 1%

ASTEPRO

ATRALIN

AXIRON

AZILECT

BEYAZ

COPAXONE 20MG/ML

INTUNIV

LOESTRIN FE

MINASTRIN 24 FE

NITROSTAT

PATADAY

PRISTIQ

STRATTERA

TACLONEX OINT

TAMIFLU

TAZORAC 0.1% CREAM

TOBRADEX SUSP

VAGIFEM VAGINAL

VELTIN

VIGAMOX

ZIANA

4. The following BRAND products will move from Preferred Brand to Non-Formulary designation due to the availability of lower cost alternatives.

ABILIFY

APRISO

BELVIQ

BESIVANCE

BEYAZ

DROXIA

DUREZOL

FOLLISTIM AQ

FOSRENOL

KALBITOR

KRISTALOSE

LOESTRIN FE

MINASTRIN

NITROSTAT

ORENITRAM

OSPHENA

PRADAXA

REVELA PACKET

STELARA IV

SUMAVEL DOSEPRO

SYNVISC/SYNVISC-ONE

UCERIS RECTAL FOAM

ZELAPAR

In 2018, immunizations will move to Preferred Brand designation to encourage patient wellness.

Allan Zaenger R.Ph., MS
Director of Pharmacy